Skip to main content

Advertisement

Table 4 Availability of interventions for PPH treatment bundle: % (95% CI)

From: Scaling up interventions: findings and lessons learned from an external evaluation of Niger’s National Initiative to reduce postpartum hemorrhage

  Phase 1 (n = 69) Phase 2 (n = 69) p-value
Step 1: Misoprostol – treatment doses
Received at least 1 procurement of misoprostol treatment doses 72.8 (55.5, 91.2) 75.3 (52.1, 89.5) P = .78
Experienced stock out within the last 12 months 24.7 (9.4, 50.8) 53.4 (33.1, 72.6) P = .06
Stock-out levels within last 12 months
 Never 75.3 (49.2, 90.6) 47.2 (27.7, 67.7) P = .07
 Less than 1 month 5.4 (1.5, 17.2) 26.6 (12.0, 49.2)
 1–3 months 10.4 (2.6, 33.1) 26.1 (10.6, 51.3)
 Over 3 months 8.9 (1.2, 44.1) 0
Expired stock at time of data collection 25.2 (11.9, 45.9) 49.8 (33.3, 66.4) P = .05
Step 2: Uterine balloon tamponade kits
Received at least 1 procurement of UBT kits 80 (61.5, 91.0) 80 (57.0, 92.0) p = .63
Experienced stock-out within the last 12 months 0.3 (0, 2.7) 23.4 (10.1, 45.4) p < .001
Stock-out levels within last 12 months
 Never 99.7 (97.3, 100) 81.8 (59.4, 93.2) p = .001
 Less than 1 month 0 2.1 (0.4, 9.3)
 1–3 months 0.3 (0, 2.7) 16.1 (5.3, 39.9)
 Over 3 months 0 0
Incomplete UBT kits in stock 9.6 (3.8, 22.3) 60.1 (41.2, 76.4) p < .001
Step 3: Non-pneumatic anti-shock garment
Functional NASG in stock 87.9 (63.3, 96.4) 91.5 (66.7, 98.3) p = .62
Quantity of NASG in stock
 None 12.1 (3.6, 33.7) 8.5 (1.7, 33.3) p = .62
 1–3 87.5 (66.3, 96.1) 91.1 (67.2, 98.1)
 4+ 0.4 (0.2, 1.1) 0.4 (0.2, 1.0)